Evaluation of anti - fibrosis effect of compound Biejia Ruangan tablets with transient elastography. (English)
In: Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi, Jg. 29 (2013-10-01), Heft 10, S. 760-763
academicJournal
Zugriff:
Objective: To evaluate the clinica efficacy of compound Biejia Ruangan tablets using transient elastography in patients with hepatitis B - induced compensated liver cirrhosis who ae concurrently treated with entecavir. Methods: In this prospective, randomized, and controlled study, 100 patients with hepatitis B - induced compensated liver ciirhosis were randomly assigned to the control group and the experimental group in a ratio of 1:1. Te patients in the control group were treated with the anti - virus drug entecavir aone, whereas the patients in the experimental group were treated with entecavir ad compound Bieeia Ruaga tablets for ati - fibrosis therapy. Te patients were foUowed up at 6 and 12 months. Ater treatment, the chages in transient elasticity values were evauated, ad the transient elasticity values were compared between the two groups. Continuous variables were compaed with the t test and categorica data as well as rates were compaed with the chi - squae test. Results: Treatment with compound Bieeia Ruanga tablets led to significatly lower transient elasticity vaues in the experimental group tha in the control group at 6 ad 12 months ( t =2. 963, P = 0. 004 ; t = 2. 239, P = 0.027 ). Transient elasticity values at 6 ad 12 months were signifi-catly lower than their respective baseline levels in the control group ( t =4. 295, P <0. 001 for compaison between values at baseline ad 6 months; t = 6. 109, P <0.001 for compaison between values at baseline ad 12 months; t = 5.394, P <0.001 for compaison between vaues at 6 ad 12 months) ad the experimental group (t = 8. 505, P <0.001 for comparison between vaues at baseline ad 6 months; t =9. 882, P <0.001 for compaison between vaues at baseline ad 12 months; t = 7. 930, P <0.001 for compaison between vaues at 6 months ad 12 months). At 12 monts, the proportion of patients with liver cirrhosis in te experimental group was significaty lower tha that in the control group (X = 4.058, P = 0.044). Conclusion: Entecavir can relieve liver fibrosis to some extent. Moreover, entecavir combined with compound Bieeia Ruagan talets can lead to further improvement in liver fibrosis at 6 ad 12 monts. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Evaluation of anti - fibrosis effect of compound Biejia Ruangan tablets with transient elastography. (English)
|
---|---|
Autor/in / Beteiligte Person: | Ning, ZHANG ; Shuangnan, ZHOU ; Man, GONG |
Zeitschrift: | Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi, Jg. 29 (2013-10-01), Heft 10, S. 760-763 |
Veröffentlichung: | 2013 |
Medientyp: | academicJournal |
ISSN: | 1001-5256 (print) |
DOI: | 10.3969/j.issn.1001-5256.2013.10.010 |
Schlagwort: |
|
Sonstiges: |
|